Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.autrev.2020.102575 http://scihub22266oqcxt.onion/10.1016/j.autrev.2020.102575 32376395!7200134!32376395     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Autoimmun+Rev 2020 ; 19 (7): 102575 Nephropedia Template TP {{tp|p=32376395|t=2020. SARS-CoV-2 infection among patients with systemic autoimmune diseases |pdf=|usr=}}{{32376395}} gab.com Text SARS-CoV-2 infection among patients with systemic autoimmune diseases JO: Autoimmun Rev http://www.kidney.de/pget.php?&tw=1&pmid=32376395 #FOAvip OBJECTIVES: This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the general Tuscan population. METHODS: In this cross-sectional study, Tuscan outpatients with systemic autoimmune diseases followed at a tertiary referral centre were telephonically interviewed between April 1st-14th 2020 to collect demographic and clinical data, information on ongoing immunomodulating/immunosuppressive treatments, and on the presence of symptoms suspected of SARS-CoV-2 or of a confirmed infection. RESULTS: 458 patients were interviewed [74% female, median age 56 years (IQR 43-68)]; 56% of them were receiving corticosteroids, 44% traditional disease-modifying anti-rheumatic drugs (DMARDs), of whom 23% hydroxychloroquine, 5% colchicine, while 41% were on biologic DMARDs (of whom 9% on tocilizumab). Thirteen patients reported symptoms suggesting SARS-CoV-2 infection. Of them, 7 had undergone nasopharyngeal swab and only one was positive and developed severe SARS-CoV-2 complications. Within our cohort, the prevalence of SARS-CoV-2 infection was therefore 0.22% (0.01-1.21%), comparable to that observed in the general population of Tuscany [0.20% (0.20-0.21%), p = .597]. CONCLUSIONS: Patients with systemic autoimmune diseases do not seem to carry an increased risk of SARS- CoV-2 infection as compared to the general population. Twit Text FOAVip SARS-CoV-2 infection among patients with systemic autoimmune diseases ????Autoimmun Rev http://www.kidney.de/pget.php?&tw=1&pmid=32376395 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32376395 #FOAvip English Wikipedia <ref>{{Cite pmid|32376395}}</ref> SARS-CoV-2 infection among patients with systemic autoimmune diseases #MMPMID32376395 Emmi G; Bettiol A; Mattioli I; Silvestri E; Di Scala G; Urban ML; Vaglio A; Prisco D Autoimmun Rev 2020[Jul]; 19 (7): 102575 PMID32376395show ga OBJECTIVES: This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the general Tuscan population. METHODS: In this cross-sectional study, Tuscan outpatients with systemic autoimmune diseases followed at a tertiary referral centre were telephonically interviewed between April 1st-14th 2020 to collect demographic and clinical data, information on ongoing immunomodulating/immunosuppressive treatments, and on the presence of symptoms suspected of SARS-CoV-2 or of a confirmed infection. RESULTS: 458 patients were interviewed [74% female, median age 56 years (IQR 43-68)]; 56% of them were receiving corticosteroids, 44% traditional disease-modifying anti-rheumatic drugs (DMARDs), of whom 23% hydroxychloroquine, 5% colchicine, while 41% were on biologic DMARDs (of whom 9% on tocilizumab). Thirteen patients reported symptoms suggesting SARS-CoV-2 infection. Of them, 7 had undergone nasopharyngeal swab and only one was positive and developed severe SARS-CoV-2 complications. Within our cohort, the prevalence of SARS-CoV-2 infection was therefore 0.22% (0.01-1.21%), comparable to that observed in the general population of Tuscany [0.20% (0.20-0.21%), p = .597]. CONCLUSIONS: Patients with systemic autoimmune diseases do not seem to carry an increased risk of SARS- CoV-2 infection as compared to the general population. |Adrenal Cortex Hormones/therapeutic use[MESH] |Adult[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |Antirheumatic Agents/therapeutic use[MESH] |Autoimmune Diseases/*complications/drug therapy[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Colchicine/therapeutic use[MESH] |Coronavirus Infections/*complications[MESH] |Cross-Sectional Studies[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Italy[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications[MESH]SARS-CoV-2 infection among patients with systemic autoimmune diseases (epmc).pdf DeepDyve Pubget Overpricing